| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Capricor Therapeutics (NASDAQ:CAPR) through any online brokerage.
Other companies in Capricor Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Capricor Therapeutics has a consensus price target of $30.86.
The stock price for Capricor Therapeutics (NASDAQ: CAPR) is $6.6563 last updated October 19, 2026 at 6:17 PM EDT.
There are no upcoming dividends for Capricor Therapeutics.
Capricor Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Capricor Therapeutics.
Capricor Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
